Gastroparesis Market 2024 – By Growth Rate, Sales, Production, Consumption Manufacturers, Shares And Outlook By 2033

The Gastroparesis Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Gastroparesis Market:
https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

According to The Business Research Company’s Gastroparesis Global Market Report 2024, The gastroparesis market size has grown strongly in recent years. It will grow from $6.44 billion in 2023 to $6.8 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%.  The  growth in the historic period can be attributed to aging population, increasing prevalence of diabetes, improved understanding of gastrointestinal disorders, evolving treatment protocols, growing awareness about gastroparesis.

The gastroparesis market size is expected to see steady growth in the next few years. It will grow to $8.19 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%.  The growth in the forecast period can be attributed to development of novel therapeutic options, expansion of personalized medicine approaches, integration of digital health solutions, rise in healthcare infrastructure, increasing focus on early diagnosis. Major trends in the forecast period include advancements in gastric electrical stimulation therapy, growing research in stem cell therapy, adoption of minimally invasive surgical interventions, increased use of wearable health monitoring devices, focus on patient-centric care models.

The increasing prevalence of gastroparesis is expected to propel the growth of the gastroparesis market. Gastroparesis is a medical condition that stops or delays food movement from the stomach to the small intestine. Hypothyroidism, autoimmune diseases, injury to the vagus nerve, and viral stomach infections cause gastroparesis. Gastroparesis medicine tightens and contracts the muscles in the stomach wall and improves gastric emptying. For instance, in 2021, according to a research study published by Practice Update, a Netherlands-based online publisher of research articles, in 2021 the overall prevalence rate of gastroparesis was 267.7 per 100,000 persons in the US. The prevalence rate of definite gastroparesis was 21.5 per 100,000 persons. As a result, the increasing prevalence of gastroparesis is driving the growth of gastroparesis treatment.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12189&type=smp

The gastroparesis market covered in this report is segmented –

1) By Treatment Modality: Medications, Dietary Modifications, Medical Devices, Other Therapies

2) By Gastroparesis Type: Idiopathic, Diabetic, Post- Surgical, Other Types

3) By Patient Demographics: Pediatric Gastroparesis, Adult Gastroparesis

4) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels

5) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Home Care Settings

Top Major Players
Pfizer Inc.
GlaxoSmithKline plc.
Abbott Laboratories Inc.
AstraZeneca Plc.
Medtronic Plc.

Major companies operating in the gastroparesis market are developing innovative devices to increase their profitability in the market. Devices for the treatment of gastroparesis are medical tools or equipment designed to help manage or alleviate symptoms associated with gastroparesis, a condition characterized by delayed emptying of the stomach. For instance, in 2022, Enterra Medical Inc., a US-based medical device company launched enterra therapy for the treatment of gastroparesis. The Enterra Therapy system employs an implanted neurostimulator to produce gentle electrical pulses, offering potential relief for symptoms of chronic nausea and vomiting linked to gastroparesis. This therapy is designated for individuals aged 18 to 70 years experiencing chronic, intractable (drug-refractory) nausea and vomiting associated with gastroparesis of diabetic or idiopathic origin.

The gastroparesis market report table of contents includes:
1. Executive Summary
2. Gastroparesis Market Characteristics
3. Gastroparesis Market Trends And Strategies
4. Gastroparesis Market – Macro Economic Scenario
5. Global Gastroparesis Market Size and Growth
…………………..
32. Global Gastroparesis Market Competitive Benchmarking
33. Global Gastroparesis Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Gastroparesis Market
35. Gastroparesis Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model